9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada)

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada)

Type 2 diabetes mellitus (T2D) is a progressive metabolic disorder characterized by peripheral insulin resistance, impaired insulin secretion by pancreatic β-cells, accelerated hepatic glucose output, and abnormal incretin axis function. The Diabetes Canada Clinical Practice Guidelines provide an evidence-based, organ-protective framework emphasizing that glycemic control must be integrated with aggressive cardiovascular and renal risk mitigation.

---

Diagnostic Criteria for Diabetes Mellitus & Prediabetes

In Canada, the diagnosis of diabetes mellitus is established using standardized laboratory assays on venous plasma. Capillary blood glucose measurements obtained from personal point-of-care glucometers are legally and clinically unacceptable for diagnostic confirmation.

Diagnostic Thresholds for Diabetes Mellitus

A diagnosis of diabetes is confirmed when any of the following four criteria are satisfied:

1. Fasting Plasma Glucose (FPG) ≥ 7.0 mmol/L (fasting defined as no caloric intake for at least 8 hours).
2. Glycated Hemoglobin (A1C) ≥ 6.5% (standardized, validated National Glycohemoglobin Standardization Program [NGSP] certified assay in non-pregnant adults).
3. Two-Hour Plasma Glucose (2hPG) in a 75 g Oral Glucose Tolerance Test (OGTT) ≥ 11.1 mmol/L.
4. Random Plasma Glucose (RPG) ≥ 11.1 mmol/L in the presence of classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss, fatigue, or blurred vision).

                               DIABETES CANADA DIAGNOSTIC CONFIRMATION WORKFLOW
                               
                                 Initial Positive Venous Blood Test
                                                │
                        ┌───────────────────────┴───────────────────────┐
                        ▼                                               ▼
            CLASSIC SYMPTOMS PRESENT?                       ASYMPTOMATIC PATIENT
          (Polyuria, Polydipsia, Weight Loss)                           │
                        │                                               ▼
                        ▼                                   Repeat Confirmatory Test
             DIAGNOSIS CONFIRMED                            (Same or alternate assay on another day)
             Initiate management immediately                            │
                                                ┌───────────────────────┴───────────────────────┐
                                                ▼                                               ▼
                                     Both Tests Exceed Threshold?                    Discordant Results?
                                                │                                               │
                                                ▼                                               ▼
                                       DIAGNOSIS CONFIRMED                     Repeat the test that was above threshold

Prediabetes Categories

Prediabetes designates glycemic levels above normal physiological reference ranges but below the diagnostic threshold for overt diabetes, identifying patients at high risk for progression to microvascular and macrovascular complications:

• Impaired Fasting Glucose (IFG): FPG 6.1 to 6.9 mmol/L.
• Impaired Glucose Tolerance (IGT): 2hPG in 75 g OGTT 7.8 to 11.0 mmol/L.
• Prediabetes A1C: A1C 6.0% to 6.4% (high risk of developing diabetes; intensive lifestyle modifications recommended).

---

Individualized Glycemic Targets & Clinical Thresholds

Diabetes Canada stresses that glycemic targets must be personalized based on clinical characteristics, patient life expectancy, duration of disease, hypoglycemia risk, and established comorbidities.

---

First-Line Pharmacotherapy: Metformin (Biguanides)

Unless contraindicated, metformin is the foundational first-line pharmacological therapy for type 2 diabetes, initiated concurrently with healthy lifestyle interventions (nutritional counseling, regular aerobic and resistance exercise, smoking cessation, and weight management).

Mechanism of Action

Metformin exerts its primary antihyperglycemic action by activating adenosine monophosphate-activated protein kinase (AMPK) in hepatic tissue. This activation suppresses hepatic gluconeogenesis and glycogenolysis, markedly reducing excessive basal glucose output. Secondarily, metformin increases peripheral glucose uptake and insulin sensitivity in skeletal muscle and reduces intestinal glucose absorption. Metformin does not stimulate pancreatic β-cell insulin release; consequently, when used as monotherapy, it does not cause hypoglycemia and is weight neutral or promotes modest weight loss (1–2 kg).

Dosing, Titration, and Adverse Effects

• Initiation & Titration: Begin with 250 mg or 500 mg orally once or twice daily with meals. Increase by 500 mg every 1 to 2 weeks to target an effective maintenance dose of 1000 mg BID (maximum approved dose is 2000–2550 mg/day in divided doses).
• Gastrointestinal Effects: Abdominal cramps, diarrhea, nausea, dyspepsia, and metallic taste occur in 20%–30% of patients. These effects are dose-dependent and typically transient. Mitigate by taking strictly with or immediately after meals and titrating gradually. Patients with persistent intolerance to immediate-release metformin can often successfully tolerate the extended-release formulation (Glumetza).
• Vitamin B12 Malabsorption: Long-term metformin use interferes with calcium-dependent absorption of the vitamin B12-intrinsic factor complex in the terminal ileum. Check serum vitamin B12 levels every 1 to 2 years, or promptly if the patient develops macrocytic anemia or worsening peripheral neuropathy.

Lactic Acidosis and Renal Dosing Thresholds

Metformin-associated lactic acidosis (MALA) is rare (3 to 10 cases per 100,000 patient-years) but carries a mortality rate of 30% to 50%. Metformin inhibits mitochondrial complex I, which reduces hepatic pyruvate carboxylase activity and impairs the conversion of lactate into glucose, predisposing to systemic lactate accumulation under conditions of tissue hypoperfusion or renal clearance failure.

                                METFORMIN RENAL SAFETY THRESHOLDS (eGFR)
                                
    eGFR ≥ 45 mL/min/1.73m²             eGFR 30 - 44 mL/min/1.73m²             eGFR < 30 mL/min/1.73m²
 ┌─────────────────────────────┐     ┌─────────────────────────────┐     ┌─────────────────────────────┐
 │ • Safe at full doses        │     │ • REDUCE DOSE BY 50%        │     │ • CONTRAINDICATED           │
 │ • Max dose: 2000-2550 mg/day│ ──> │ • Max dose: 1000 mg/day     │ ──> │ • DISCONTINUE IMMEDIATELY   │
 │ • Monitor eGFR annually     │     │ • Monitor eGFR q3-6 months  │     │ • High lactic acidosis risk │
 └─────────────────────────────┘     └─────────────────────────────┘     └─────────────────────────────┘

---

Second-Line Organ-Protective Pharmacotherapy: SGLT2 Inhibitors & GLP-1 Receptor Agonists

The Diabetes Canada guidelines mandate an organ-protective paradigm: all patients with T2D must be screened for cardiovascular and renal comorbidities. If established atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), or chronic kidney disease (CKD) is present, an agent with proven outcome benefits must be added regardless of whether the baseline A1C is at target.

                             DIABETES CANADA SECOND-LINE DECISION TREE
                             
                     Patient with Type 2 Diabetes (on Metformin or Metformin-intolerant)
                                                │
                       Assess for Organ-Specific Comorbidities Regardless of A1C
                                                │
      ┌─────────────────────────────────┼─────────────────────────────────┐
      ▼                                 ▼                                 ▼
  ESTABLISHED ASCVD                HEART FAILURE (HFrEF/HFpEF)       CHRONIC KIDNEY DISEASE
  (Prior MI, Stroke, PAD, CAD)      (LVEF ≤ 40% or Preserved)        (eGFR 20-60 or ACR > 3 mg/mmol)
      │                                 │                                 │
      ▼                                 ▼                                 ▼
  Add GLP-1 RA or SGLT2i            Add SGLT2 Inhibitor               Add SGLT2 Inhibitor
  with proven CVOT benefit          (Empagliflozin or Dapagliflozin)  (Dapagliflozin or Empagliflozin
  • GLP-1 RA: Semaglutide,          Demonstrated hospital reduction   or Canagliflozin)
    Dulaglutide, Liraglutide        and CV death reduction            Slows renal progression;
  • SGLT2i: Empagliflozin,                                            GLP-1 RA if SGLT2i unsuitable
    Canagliflozin, Dapagliflozin

1. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

• Agents: Empagliflozin (Jardiance), Dapagliflozin (Forxiga), Canagliflozin (Invokana).
• Mechanism: Inhibits SGLT2 proteins located in the early S1 segment of the proximal convoluted renal tubule. By blocking the reabsorption of filtered glucose and sodium, SGLT2 inhibitors induce glucosuria (50–100 g glucose/day, representing 200–400 kcal/day) and mild natriuresis, lowering plasma glucose, body weight (2–3 kg), and systolic blood pressure (2–4 mmHg).
• Cardiorenal Protection: Restores tubuloglomerular feedback by increasing distal sodium delivery to the macula densa, promoting afferent arteriolar constriction and normalizing elevated intraglomerular pressure (mitigating diabetic hyperfiltration). Robustly reduces heart failure hospitalizations, cardiovascular mortality, and progression of diabetic kidney disease.
• Adverse Effects & Clinical Pearls:
  • Mycotic Genital Infections: Vulvovaginal candidiasis and candida balanitis occur in 5%–10% of patients due to glucosuria. Advise daily perineal hygiene; treat with standard topical or oral antifungals without necessarily discontinuing the drug.
  • Volume Depletion & Hypotension: Osmotic diuresis increases urine volume by 300–500 mL/day. Assess orthostasis; consider reducing baseline loop diuretic doses in frail elderly individuals.
  • Euglycemic Diabetic Ketoacidosis (euDKA): Severe metabolic acidosis presenting with minimal hyperglycemia (< 14.0 mmol/L) or euglycemia. Precipitated by acute infection, acute surgery, severe carbohydrate restriction, or insulin deficiency. The mechanism involves glucosuria-induced suppression of insulin secretion and elevation of glucagon, stimulating hepatic ketogenesis while renal glucosuria masks hyperglycemia.
  • Fournier's Gangrene: Rare but life-threatening necrotizing fasciitis of the perineal and perianal tissues requiring urgent surgical debridement.

2. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

• Agents: Semaglutide (Ozempic [SC weekly], Rybelsus [PO daily]), Dulaglutide (Trulicity [SC weekly]), Liraglutide (Victoza [SC daily]).
• Mechanism: Synthetic analogs resistant to degradation by dipeptidyl peptidase-4 (DPP-4) that bind GLP-1 receptors, enhancing glucose-dependent insulin secretion from β-cells, suppressing inappropriate postprandial glucagon secretion from α-cells, delaying gastric emptying, and promoting central hypothalamic satiety, producing significant weight reduction (4% to >15%).
• Cardiorenal Protection: Proven reduction in three-point Major Adverse Cardiovascular Events (3P-MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) and composite renal endpoints in large clinical outcome trials.
• Adverse Effects & Administration Nuances:
  • Gastrointestinal Disturbance: Nausea, vomiting, diarrhea, and constipation are frequent (15%–30%). Titrate doses slowly at 4-week intervals (e.g., semaglutide SC: 0.25 mg weekly for 4 weeks, then 0.5 mg weekly, titrating to 1.0 mg or 2.0 mg as needed).
  • Oral Semaglutide Administration: Must be taken immediately upon waking on an empty stomach with a small volume of plain tap water (≤ 120 mL); the patient must wait at least 30 minutes before consuming any food, beverages, or other oral medications to ensure absorption across the gastric mucosa facilitated by the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate).
  • Pancreatitis: Counsel on recognizing persistent, severe epigastric pain radiating to the back; discontinue immediately if acute pancreatitis is suspected.
  • Black Box Contraindication: Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), secondary to C-cell hyperplasia observed in rodent bioassays.

---

Additional Non-Insulin Antihyperglycemic Classes

When organ-protective agents are contraindicated, not tolerated, or additional glycemic lowering is needed to achieve individualized A1C targets, alternative non-insulin classes are considered:

1. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Gliptins)

• Agents: Sitagliptin (Januvia), Linagliptin (Trajenta), Saxagliptin (Onglyza).
• Mechanism: Inhibit the DPP-4 enzyme, slowing the enzymatic degradation of endogenous incretins (GLP-1 and GIP), thereby increasing active incretin hormones and stimulating glucose-dependent insulin secretion while curbing glucagon release.
• Clinical Profile: Modest A1C reduction (0.5%–0.7%), weight neutral, negligible hypoglycemia risk.
• Renal Dosing Differences:
  • Sitagliptin: Renally eliminated. Dose adjustment required: 100 mg daily if eGFR ≥ 45 mL/min/1.73 m²; 50 mg daily if eGFR 30–44 mL/min/1.73 m²; 25 mg daily if eGFR < 30 mL/min/1.73 m².
  • Linagliptin: Primarily eliminated via enterohepatic bile excretion (>80% in feces). Requires no dose adjustment for any degree of renal impairment or hepatic dysfunction (5 mg once daily regardless of eGFR).
  • Heart Failure Precaution: Saxagliptin is associated with an increased risk of heart failure hospitalization and should be avoided in patients with or at risk for heart failure.

2. Sulfonylureas (Secretagogues)

• Agents: Gliclazide (Diamicron / Diamicron MR), Glimepiride, Glyburide (Diabeta).
• Mechanism: Bind to specific sulfonylurea receptors (SUR1) associated with ATP-sensitive potassium channels on pancreatic β-cells, causing channel closure, membrane depolarization, calcium influx, and exocytosis of preformed insulin granules independent of ambient glucose concentrations.
• Agent Selection & Renal Hazards:
  • Gliclazide is the preferred sulfonylurea in Canada due to reversible SUR1 binding, a significantly lower incidence of severe hypoglycemia, and inactive hepatic metabolites.
  • Glyburide is obsolete and should be avoided, particularly in elderly individuals and those with renal impairment. Glyburide is metabolized into active, renally eliminated metabolites that accumulate as eGFR declines, triggering prolonged, refractory hypoglycemia requiring multiple days of continuous intravenous dextrose.

3. Thiazolidinediones (TZDs / Glitazones)

• Agent: Pioglitazone (Actos).
• Mechanism: Highly selective agonist for the peroxisome proliferator-activated receptor-gamma (PPAR-γ) nuclear transcription factor. Enhances insulin sensitivity in skeletal muscle, liver, and adipose depots; lowers insulin resistance without stimulating pancreatic secretion.
• Adverse Effects & Strict Contraindications:
  • Fluid Retention & Heart Failure: Causes renal distal tubule sodium reabsorption and plasma volume expansion, causing peripheral edema and precipitating or worsening congestive heart failure. The Canadian pioglitazone monograph contraindicates it in any patient with heart failure or a history of heart failure (NYHA Class I to IV); the American label restricts only Class III or IV.
  • Distal Bone Fractures: Increased fracture incidence, particularly in postmenopausal females.
  • Delayed Onset: Slow onset of therapeutic benefit; maximal glycemic reduction requires 8 to 12 weeks of consistent therapy.

---

Comparative Matrix of Non-Insulin Antihyperglycemic Agents

---

Canadian Sick-Day Medication Management: The SADMANS Mnemonic

During acute dehydrating illnesses (e.g., severe gastroenteritis with vomiting and diarrhea, febrile infections, or perioperative fasting), systemic volume depletion impairs renal perfusion. Taking certain chronic medications during this vulnerable window dramatically elevates the risk of acute kidney injury (AKI), dangerous drug accumulation, or metabolic crises.

Diabetes Canada recommends that pharmacists educate all diabetic patients on the SADMANS mnemonic, instructing them to temporarily withhold these medications during acute dehydrating illness until normal oral hydration is restored for at least 24 to 48 hours:

                                  THE SADMANS SICK-DAY PROTOCOL
                                  
 S ──> Sulfonylureas (Gliclazide, Glimepiride, Glyburide)   ──> Hypoglycemia risk when food intake drops
 A ──> ACE Inhibitors (Ramipril, Perindopril, Enalapril)     ──> Loss of efferent arteriolar tone -> AKI
 D ──> Diuretics (Furosemide, Hydrochlorothiazide, Indapamide) ──> Severe dehydration, volume collapse & AKI
 M ──> Metformin (Glucophage, Glumetza)                    ──> Tissue hypoperfusion -> Lactic acidosis
 A ──> Angiotensin Receptor Blockers (Candesartan, Telmisartan) ──> Loss of efferent arteriolar tone -> AKI
 N ──> Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)        ──> Inhibits afferent prostaglandins -> AKI
 S ──> SGLT2 Inhibitors (Empagliflozin, Dapagliflozin)      ──> Dehydration, AKI & Euglycemic DKA

---

Clinical Case Vignette: Pharmacotherapy Selection in Complex Type 2 Diabetes

A 63-year-old male with an 8-year history of type 2 diabetes presents to the outpatient clinic for a comprehensive medication review. His current medication regimen consists solely of metformin 1000 mg PO BID.

Clinical Assessment Findings:

• Laboratory Results: A1C 8.4%, FPG 9.6 mmol/L, Serum Creatinine 120 μmol/L, eGFR 54 mL/min/1.73 m², Urine Albumin-to-Creatinine Ratio (ACR) 8.2 mg/mmol (moderately increased albuminuria / diabetic kidney disease).
• Cardiovascular History: Non-ST elevation myocardial infarction (NSTEMI) 3 years ago; coronary stent placed in LAD.
• Physical Exam: Blood pressure 134/82 mmHg, heart rate 72 bpm, BMI 31.8 kg/m², no peripheral edema.

Pharmacotherapeutic Care Plan:

1. A1C Target Evaluation: Standard target is ≤ 7.0%. At 8.4%, intensification of antihyperglycemic therapy is clearly required.
2. Metformin Renal Appropriateness: His eGFR is 54 mL/min/1.73 m², which falls comfortably above the 45 mL/min/1.73 m² threshold. Metformin 1000 mg BID remains safe and appropriate at full dose; recheck eGFR every 6 months.
3. Second-Line Agent Selection: The patient possesses two major organ-protective indications under Diabetes Canada guidelines: established ASCVD (prior MI) and chronic kidney disease (eGFR < 60 and ACR > 3 mg/mmol). Adding an SGLT2 inhibitor (e.g., empagliflozin 10 mg daily or dapagliflozin 10 mg daily) provides proven secondary cardiovascular event reduction and slows diabetic nephropathy progression. Alternatively, adding a GLP-1 receptor agonist with proven CVOT benefit (e.g., semaglutide SC 0.25 mg weekly, titrated to 0.5 mg or 1.0 mg) offers robust 3P-MACE reduction, favorable nephropathy outcomes, and substantial weight loss for his Class I obesity.
4. Patient Education: Counsel on perineal hygiene and the signs of euDKA if an SGLT2 inhibitor is initiated, and review the SADMANS sick-day rules to temporarily hold his metformin and SGLT2 inhibitor if acute dehydrating illness strikes.